2'''',4″-O-双(三甲基硅)-6-O-甲基红霉素A9-O-(1-甲氧基环己基)肟的区域选择性合成机理及其晶体结构

克拉霉素(Clarithromycin)是第二代十四元大环内酯抗生素, 其合成是保护技术应用和区域选择性研究的一次集中体现[1,2].目前, 美国雅培实验室和日本大正公司是以2′,4″-O-双(三甲基硅)红霉素A 9-O-(1-异丙氧环己基)肟(1)作为区域选择性前体制备的[1,3]; 而中国和印度制药企业多采用2′,4″-O-双(三甲基硅)红霉素A 9-O-(1-甲氧基-1-甲基乙基)肟(2)作为关键中间体[4,5].后者的主要杂质为6,11-O-双甲基红霉素A[6].对大环内酯的区域选择性进行了大量的研究后, 发现2′,4″-O-双(三甲基硅)红霉素A 9-O-(1-甲氧基环己基)肟(3)的区域选择性远低于空间结构差异不大的化合物1[7], 却与空间结构差异较大的化合物2一样, 易生成大量的6,11-O-双甲基化产物.     

2’，4”-O-双(三甲基硅)-6-O-甲基红霉素A 9-O-(1-甲氧基环己基)肟的区域选择性合成机理及其晶体结构

合成了化合物3的6-OH区域选择性甲基化产物, 即2',4"-O-双(三甲基硅)-6-O-甲基红霉素A 9-O-(1-甲氧基环己基)肟(4)的单晶, 以及化合物2的单晶, 并确定了其立体构型, 以期阐明区域选择性与大环内酯构象之间的关系.     

E-、Z-2-(1-咪唑基)-O-（α-甲基对卤苄基）-2′，4′-二氯苯乙 酮肟硝酸盐的合成与结构表征

首先以2,4-二氯氯代苯乙酮、咪唑、羟胺和对卤苯乙酮为原料,分别合成E-、Z-2-（1-咪唑基）-2′,4′-二氯苯乙酮肟(ⅠE、ⅠZ)和对卤-α-氯乙苯（ⅡA和ⅡB）,ⅠE和ⅠZ分别与ⅡA和ⅡB反应,生成E-、Z-2-（1-咪唑基）-O-（α-甲基对卤苄基）-2′,4′-二氯苯乙酮肟硝酸盐四个新化合物,产率为52.0%～60.0%,并经元素分析、IR和1HNMR进行了表征。     

反相高效液相色谱分离红霉素肟的醚化产物的构型异构体

1　引　　言克拉霉素 (clarithromycin)是第二代大环内酯类抗生素 ,是红霉素A的 6 OH的甲基化衍生物。主要合成途径是红霉素A经肟化、醚化、硅烷化保护 ,再选择性甲基化 ,最后脱保护、脱肟而制得。其中肟羟基的醚化保护是实施工艺改进最关键的一步。我们采用 1 乙氧基环己烯为醚化试剂 ,对克拉霉素进行了合成新工艺的研究 ,取得重要突破。由于红霉素肟(oxime)有两种异构体 ,相应的其醚化产物 (ECHoxime)也有两种构型异构体 :(E) 红霉素A 9 (1 乙氧环己基 )肟和(Z) 红霉素A 9 (1 乙氧环己基 )肟 ;另外产品中还有原料带进的工艺杂质…     

E-、Z-2＇-(1-咪唑基)-O-(α-甲基-二氯苄基)-2,4-二氯苯乙酮肟硝酸盐的合成与抑菌活性

E-、Z-2＇-(1-咪唑基)-O-(α-甲基-二氯苄基)-2;4-二氯苯乙酮肟硝酸盐的合成与抑菌活性     

含次环己基的有机硅单体及其低聚体的合成

硅氯仿和环己二烯-1,3进行硅氢加成反应,生成1,3-双(三氯硅基)环己烷,经醇解制得1,3-双(三乙氧硅基)环己烷,与溴化甲基镁反应,制得1,3-双(二乙氧甲硅基)环己环、1-(乙氧二甲硅基)-3-(二乙氧甲硅基)环己烷和1,3-双(乙氧二甲硅基)环己烷,它们在盐酸溶液中分别进行水解,得到各种含次环己基的有机硅低聚体,其中2,2,4,4,11,11,13,13-八甲基-3,12-二氧(杂)-2,4,11,13-四硅(杂)三环[11,3,1,1~(5,9)]十八烷和D_4相似,可能经开环聚合得到聚硅次环己基硅氧烷。     

天然产物Combretastatin A-1和Combretastatin B-1的合成

基于Perkin反应策略合成了具有强效抗肿瘤、抗血管活性的天然产物Combretastatin A-1(CA1)和Combretastatin B-1(CB1).以2,3,4-三羟基苯甲醛(1)为起始物, 经单甲基化反应得到2,3-二羟基-4-甲氧基苯甲醛(2), 再经酚羟基保护得到2,3-二异丙基-4-甲氧基苯甲醛(3), 该化合物与3,4,5-三甲氧基苯乙酸(4)发生Perkin反应分离得到E-2-(3,4,5-三甲氧基苯基)-3-(2',3'-二异丙氧基-4'-甲氧基)丙烯酸(E-5), 经脱羧反应得到Z-3,4,4',5-四甲氧基-2',3'-二异丙氧基二苯乙烯(6), 最后经脱保护反应得到CA1.另外, 将E-2-(3,4,5-三甲氧基苯基)-3-(2',3'-二异丙氧基-4'-甲氧基)丙烯酸(E-5)脱去保护基得到E-2-(3,4,5-三甲氧基苯基)-3-(2',3'-二羟基-4'-甲氧基)丙烯酸(7), 该化合物经脱羧-异构化反应得到E-3,4,4',5-四甲氧基-2',3'-二羟基二苯乙烯(E-CA1), 最后经催化氢化得到CB1.     

E-、Z-2’-(1-咪唑基)-O-(α-甲基-二氯苄基)-2,4-二氯苯乙酮肟硝酸盐的合成与抑菌活性

以间二氯苯、氯乙酰氯和咪唑为原料 ,利用成肟和引入咪唑基顺序不同 ,首先合成了 E-,Z-2 -(1 -咪唑基 ) -2 ,4 -二氯苯乙酮肟 ( E、IZ) ,从二氯苯合成了 α-氯 -二氯取代乙苯 ( A、 B和 C) ,咪唑基 -二氯苯乙酮肟顺反异构体 ( Z、 E)分别与 α-氯 -二氯乙苯反应 ,生成 E-、Z-2 -(1 -咪唑基 ) -O-(α-甲基 -二氯苄基 ) -2 ,4 -二氯苯乙酮肟硝酸盐共 6种新化合物 ,产率为 5 7.5 %～ 64 .5 %,新化合物结构经元素分析、IR和 1H NMR表征 .初步实验表明 ,各化合物对水稻苗腐根有不同程度抑制活性 .     

红霉素A9-（1-异丙氧基环已基）肟的合成及其晶体结构

合成表征了红霉素A9-（1-异丙氧基环已基）肟的E和Z异构体，并在丙酮-水混 合溶液中培养出了前者的单晶，X射线衍射表明，其结构为正交晶系，P2_12_12_1 空间群，晶胞参数：a=2.3101(5) nm, b=2.3761(5) nm, c=0.97066(19)nm, V=5. 3279(8) nm~3，Z=4，μ=0.088 mm~(-1)，F(000)=2064, D_c=1.176 g/cm~3。E-红 霉素A 9-（1-异丙氧基环已基）肟的晶体结构图明显表明1-异丙氧基环已基保护基 确实使十四元大环的构象发生了扭曲，使6-OH的周围空间不再拥挤，从而导致6- OH甲基化的选择性提高。     

吡啶桥联的聚酰亚胺的合成与性能研究

以3,4-二甲基苯乙酮与3,5-双(三氟甲基)苯甲醛为原料,通过Chichibabin反应制备了吡啶桥联的四甲基化合物,该化合物再经氧化、脱水反应制备了主链含有吡啶环、侧链带有双三氟甲基取代苯侧基的新型含氟芳香族二酐单体,2,6双(3′,4′-二羧基苯基)-4-(3″-,5″-双三氟甲基苯基)吡啶二酐(6FDAPA).FT IR、NMR、质谱以及元素分析等测试结果表明,6FDAPA的结构与预期的相符.利用6FDAPA与另外一种不含氟的二酐单体2,6双(3′,4′二羧基苯基)4苯基吡啶二酐(DAPA)分别与含氟二胺单体,1,4双(2三氟甲基4氨基苯氧基)苯(6FAPB)通过两步热亚胺化法制备了两种聚酰亚胺(PI)薄膜.测试结果表明,6FDAPA6FAPB(PI2)与DAPA6FAPB(PI1)相比具有相近的耐热性能,玻璃化转变温度为280℃,起始热分解温度为580℃、700℃时的重量保持率64.5%.同时PI2具有更为优良的透光性,紫外可见光谱(UV Vis)测试表明,PI2与PI1薄膜在450nm处的透光率分别为85.7%与69.4%.     

克拉霉素的合成新方法

以醚化剂1-乙氧基环己烯和硅烷化试剂1,1,1,3,3,3-六甲基二硅氨烷为保护试剂, 采用醚化-硅烷化保护法制备了克拉霉素. 以红霉素A肟为原料计算, 经肟羟基醚化、2',4"-OH硅烷化、6-OH选择性甲基化、脱保护至克拉霉素, 四步反应总收率为49.5%.     

Regioselectivity and crystal structure of erythromycin A oxime ketal derivatives

Three crystal structures of 2′, 4″-O-bis(trimethylsilyl) erythromycin A oxime ketal derivatives were determined and compared. Analogous protective groups on 9-oxime possessed various conformations, which resulted in very different steric congestion around 11-OH. The study on the conformations revealed the origin of the difference of regioselectivity as well as the reversal of selectivity from 11-OH to 6-OH.     

Studies on macrolide antibiotics I. Synthesis and antibacterial activity of erythromycin A 9-O-substituted oxime ether derivatives against Mycobacterium avium complex

A series of erythromycin A 9-O-substituted oxime ether derivatives have been synthesized and evaluated for antibacterial activity against Mycobacterium avium complex (MAC) and Staphylococcus aureus. These compounds possessed stronger in vitro activity against MAC including macrolide-resistant strains than clarithromycin (2), although in vitro antibacterial activities of these compounds were less than that of 2 against Staphylococcus aureus. Our studies found that several factors contribute to the antibacterial activity against MAC. The length and spatial orientation of the substituent at 9-position were found to significantly influenced the anti-MAC activity, especially against macrolide-resistant strains. Of all the compounds prepared, erythromycin A 9-[O-(4-phenylbutyl)oxime] (12q) and erythromycin A 9-[O-(3-phenoxypropyl)oxime] (12t) possessed 16 times stronger antibacterial activity than 2 against clarithromycin-resistant strains. Surprisingly, the minimum inhibitory concentrations (MICs) of 12q and 12t against the resistant strains were almost same as those against the susceptible strains. These results suggest that the erythromycin A 9-O-substituted oxime ether derivatives would be promising macrolide antibiotics.     

Column and thin-layer chromatographic methods for the simultaneous determination of acediasulfone in the presence of cinchocaine, and cefuroxime in the presence of its hydrolytic degradation products

Column liquid chromatography (LC) and thin-layer chromatography (TLC)-densitometry methods are described for simultaneous determination of acediasulfone (Ace) and cinchocaine (Cinco). In the LC method, the separation and quantitation of the 2 drugs was achieved on a Zorbax C8 column (5 microm, 150 x 4.6 mm id) using a mobile phase composed of methanol-phosphate buffer, pH 2.5 (66 + 34, v/v), at a flow rate of 1 mL/min and ultraviolet detection at 300 and 327 nm for Ace and Cinco, respectively. The method showed linearity over concentration ranges of 20-200 and 45-685 microg/mL, respectively. In the TLC-densitometry method, a mobile phase composed of methanol-tetrahydrofuran-acetic acid (45 + 5 + 0.5, v/v/v) was used for the separation of the 2 drugs. The linearity range was 0.5-4 and 2-9 microg/spot, respectively. In addition, stability indicating TLC-densitometry method has been developed for determination of cefuroxime sodium in the presence of 5-70% of its known hydrolytic degradation products. The mobile phase butanol-methanol-tetrahydrofuran-concentrated ammonium hydroxide (50 + 50 + 50' + 5, v/v/v/v) was used. The concentration range was 2-10 microg/spot. The optimized methods proved to be specific and accurate for the analysis of the cited drugs in laboratory-prepared mixtures and dosage forms. The obtained results agreed statistically with those obtained by the reference methods.     

2',4"-O-双(三甲基硅)红霉素A 9-O-(1-乙氧基-1-甲基乙基)肟的区域选择性甲基化

一锅煮合成并表征了2',4"-O-双(三甲基硅)红霉素A 9-O-(1-乙氧基-1-甲基乙基)肟, 首次在丙酮-水混合溶剂中培养出了单晶. X射线衍射表明, 其结构为四方晶系, I4空间群, 晶胞参数: a＝b＝2.9536(1) nm, c＝1.4488(1) nm, V＝12.63897(4) nm³, Z＝8, R＝0.068, wR＝0.067. 对区域选择性影响因素的研究表明: 甲基化时溶液浓度应控制0.052 mol/L和0.067 mol/L之间; 分别采用了四氢呋喃、二氯甲烷、甲基叔丁基醚、甲苯与二甲亚砜作为混合溶剂进行甲基化反应, 发现在甲苯-二甲亚砜中的效果最好, 6-OH的甲基化选择性可达到81.69%.     

2,6-二甲基-3,5-二氯-4-吡啶酚糖苷的合成

在相转移催化条件下, 使 a-D-乙酰基化溴代的葡萄糖、半乳糖、葡萄糖醛酸甲酯1a, 1b, 1c分别与2,6-二甲基-3,5-二氯-4-吡啶酚(俗称氯吡醇, 氯羟吡啶)作用, 合成了氯吡醇的糖苷: 1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4,6-四-O-乙酰基-β-D-葡萄吡喃糖苷(2a), 1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4,6-四-O-乙酰基β-D-半乳吡喃糖苷(2b), 1-O-(2'6'-二甲基-3',5'-二氯-4'-吡啶基)-2,3,4-三-O-乙酰基-β-D-葡萄吡喃糖醛酸甲酯(2c)。2a, 2b, 2c分别在甲醇中氨解, 相应得到: 1-O-(2', 6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-葡萄吡喃糖苷(3a), 1-O(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-半乳吡喃糖苷(3b),1-O-(2', 6'-二甲基-3',5'-二氯-(4'-吡啶基)-β-D-葡萄吡喃糖醛酸酰胺(3c)。2c用CH~3ONa/CH~3OH处理, 得到1-O-(2',6'-二甲基-3',5'-二氯-4'-吡啶基)-β-D-葡萄吡喃糖醛酸甲酯(3d)。     

4',5'-Dichloro-2',7'-dimethoxy-5(6)-carboxyfluorescein (JOE): synthesis and spectral properties of oligonucleotide conjugates

A convenient procedure for the preparation of the fluorescent dye 4',5'-dichloro-2',7'-dimethoxy-5(6)-carboxyfluorescein (JOE) is reported; the overall yield achieved starting from isovanillin is 10 times higher (40% vs 4%) compared to the known procedure. Isomers (5- and 6-) are easily chromatographically separable as pentafluorophenyl esters of 3',6'-O-bis(cyclohexylcarbonyl) derivatives. Four non-nucleoside JOE phosphoramidites based on 5- and 6-isomers and flexible 6-aminohexanol (AH) or rigid 4-trans-aminocyclohexanol (ACH) linkers have been prepared and used for oligonucleotide labeling. Spectral and photophysical properties of 5'-JOE-modified oligonucleotides have been studied. Fluorescence quantum yield of the dye correlates with the nature of the linker (rigid vs flexible) and with the presence of dG nucleosides in close proximity to a JOE residue.